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Introduction  
 
The AT1 receptor antagonists are reported to 
exert their anti-stress and anti-anxiety proper-
ties by modulating, in part, the HPA axis and 
three interacting cortical systems: CRF, GABA 
Type A receptors (GABAA), and noradrenaline 
[2]. Stimulation of AT1 receptors in the paraven-
tricular nucleus (PVN) by angiotensin (Ang II) 
increases CRF production and is important for 
the induction of anxiety; indeed, CRF1 receptor 
antagonists have been shown to decrease 
stress-induced anxiety [6]. 
 
The inhibition by AT1 receptor antagonists is 
sufficient to block stress-induced changes in 
CRF1 receptors and restores the inhibitory effect 
of the cortical GABAA system [7]. Importantly the 
CRF and GABA systems are tightly intercon-
nected within the paraventricular nucleus, an 
area which contains high numbers of AT1 recep-
tors and where losartan has been shown to 
cross the blood brain barrier and exert its ef-
fects  [8,9]. 
 
Ang II can also potentiate neurotransmission; 
hence, blockade of the Ang II system with spe-
cific antagonists may hyperpolarise the mem-
brane potential of sympathetic neurons, result-
ing in normalisation of their activity. Further, AT1 
receptor facilitates catecholamine release 
throughout the AT1 pre-synaptic receptor 
mechanism and blockade of this via losartan 
may have a beneficial anti-anxiety effect [10]  
 
There is however, within-strain and inter-strain 
variation in the responses of rodents to various 
paradigms of anxiety which highlights an ‘order’ 
of anxiety, whereby some mice strains show 
higher levels of anxiety compared with others. 
Some strains, such as the C57BL/6, have been 
described as non-emotive, while the contrary 
has been described for DBA2, BALB/C and A/J 
mouse strains [11,12]. Observations of 
C57BL/6J and BALB/C also show that the for-
mer are non-anxious, while mice the latter are 
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much less active and generally more anxious 
[13]; suggesting that performance in the EPM 
and LD is markedly influenced by genetic varia-
tion between strains.  
 
The angiotensin receptor associated protein 
(ATRAP/AGTRAP) is known to act as a negative 
regulator of AT1 receptor signalling and is re-
ported to potentiate Ang II signalling effects. 
Indeed, overexpression of ATRAP results in a 
marked decrease of agonist induced AT1A medi-
ated activation of phospholipase C [14], re-
duces the number of AT1 receptors at the cell 
surface [15] and negatively regulates promoter 
transcription and protein synthesis. 
 
In this study strain differences to the anxiolytic 
response to losartan were investigated in mice 
focusing on areas of genetic variation that may 
influence strain specific responses. This in-
cludes: AT1 receptor sequence variation, the 
angiotensin II receptor associated protein 
(ATRAP) and receptor expression differences 
between strains. 
 
Materials ans methods 
 
Animal treatment and husbandry 
 
All behavioural experiments were licensed un-
der the UK Scientific Procedures (Animals) Act, 
1986. Male mice of each of strain (BKW,  DBA2 
and C57, 19-30g) were bred and reared in-
house under identical conditions, consisting of 
housing in North Kent M1/M2 cages on flake 
sawdust bedding in an air conditioned room 
(approx 19ºC +/- 1ºC; humidity 50% +/-10%) 
under a 14/10-h light/dark cycle, commencing 
07:00 to 21:00. The subjects had free access to 
food and water.  
 
PCR 
 
PCR amplification was carried out using a Hy-
baid touchdown thermal cycler using standard 
thermal cycling conditions. PCR products were 
then electrophoresed on a 2% Agarose gel for 1 
hour at 80V, stained and visualised using 
ethidium bromide. DNA samples were se-
quenced using the forward primer used for ini-
tial PCR by Cogenics UK (Primer details avail-
able upon request). 
  
Mice were sacrificed and had their brains imme-
diately removed. Hypothalamic brain tissue was 
used to isolate total RNA using the guanidine 
isothiocyanate enhanced TRIzol method 
(Invitrogen, UK). RNA integrity was determined 
spectrophotometrically and only RNA with a A260
\A280 ratio above 1.8 was used for reverse tran-
scription. 1ug of RNA was treated with Turbo 
DNase I (Ambion) before being reverse tran-
scribed using BIO-RAD Iscript RT PCR kit with 
random oligo(dT) primers.  
 
AT1­R and Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) gene expression was analysed 
using the 2(ΔΔCt) method [16]. Primers and 
probes were designed using Perlprimer [17] and 
were developed to span Intron/Exon boundaries  
and to ensure specificty to  AT1a, by avoiding 
regions of high similarity and designing primers 
in the  5' untranslated region. The primers and 
probe were synthesised by MWG Biotech; n=3 
in triplicate in all cases. Confirmation of product 
specificity by size was established by melt curve 
analysis and where agarose gel electrophoresis 
revealed single specific PCR products. 
 
The initial real-time PCR resulted in greater vari-
ance across replicates than anticipated. For this 
reason a subsequent duplication was per-
formed. However, the nature of the ΔΔCt analysis 
does not lend itself readily to the simple addi-
tion of data from two independent observations, 
hence a simple Bayesian approach was em-
ployed, following the procedure outlined in Box 
& Tiao [18] and Quinn & Keough [19]. The 
mean and variance in ΔΔCt values from the first 
round of real-time PCR were used to set up the 
prior distribution, which was assumed to be 
normally distributed. The standardised likeli-
hood function was normally distributed with the 
mean ΔΔCt value of the second round of real-
time experiments and variance equal to the 
squared standard error of this mean. The mean 
of the posterior distribution is 
, is the 
estimate of the prior variance, s2 is the second 
sample  variance, is the mean of the prior 
distribution and is the mean of the second 
sample. The variance of the posterior distribu-
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tion is .  
 
Data analysis and statistical comparisons 
 
Statistical comparisons were performed using 
Minitab 15 (Minitab Solutions). Bayesian analy-
sis and RT-PCR calculations were analysed us-
ing Microsoft Excel (Microsoft). P<0.05 was con-
sidered statistically significant 
 
Results 
 
AT1  sequencing  
 
Sequencing of exon 3 of AT1ΔΔR which contains 
the entire open reading frame (MGI:87964) 
revealed no differences between BKW mice 
(n=6)  and the reference C57 and DBA2 strains 
(n=3) . Comparisons of the sequencing data 
using ClustalW alignment showed that AT1 R 
sequence was identical between strains. 
 
AT1 RT-PCR expression analysis 
 
The posterior probability distributions of mean 
ΔΔCt values are given in Figure 1. Comparisons 
of C57 and BKW show significant differences 
between strains, represented by the non-
overlapping 95% confidence intervals. In sum-
mary C57 shows significantly different AT1R ex-
pression levels to the BKW strain. 
 
ATRAP- Functional mutation A-V  
 
Sequencing of ATRAP hydrophilic domains iden-
tified a non-synonymous point mutation result-
ing in (T/C) transversion at position 157 in the 
hydrophilic tail domain (position 109-161) (SNP 
id = rs13467517). This results in a Valine   
Alanine (V157A) amino acid change in the  BKW 
and DBA2 strains (Figure 2 and 3).    
 
Discussion 
 
The anxiolytic effect of AT1 antagonists has 
been demonstrated in rodents by several 
groups [3,4,5,10,20) although some effects are 
reported as strain specific. The results pre-
sented herein demonstrate that the previously 
reported strain dependent effects are not due 
to variation in AT1a receptor sequence. How-
ever, differences in AT1 gene expression levels 
between strains are observed whereby BKW 
and DBA2 strains show higher expression com-
pared to C57, which mirrors their anxiety pheno-
type. This is coupled with a non-synonymous 
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Figure 1. Posterior probability distributions for the 
mean DDCt values across strains.  
Figure 2. Diagrammatic representation of ATRAP V-
157-A  mutation in C57, DBA2 and BKW mice. BKW 
and DBA2 mice differ from C57 strains resulting in a 
Valine to Alanine substitution at position 157. (n=6). 
Figure 3. A. Representative sequence data of ATRAP 
in C57 strain. B. Representative sequence data of a 
mutation in ATRAP. DBA2 and BKW strains show T/C 
base transversion. 
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single nucleotide polymorphism in ATRAP, a 
negative regulator of AT1 signalling.  
 
The findings in this study show that AT1 receptor 
sequence is identical between strains and, 
while no differences in AT1 receptor sequence 
were observed, RT-PCR expression analysis of 
hypothalamic AT1 receptors revealed differ-
ences in expression: BKW mice showed the 
highest levels of expression and DBA2 mice an 
intermediate level, when compared to the C57 
strain 
 
In previous studies by Gard et al, [5] BKW mice 
showed the highest anxiety‑like behaviour in 
the L/D and EPM test followed by DBA2 and 
C57.  These observations are consistent with 
others where the C57 strain are reported as 
“low anxiety” with significantly lower anxiety 
than DBA2 mice [12, 21] . The low level of anxi-
ety in C57 mice and the higher levels of anxiety 
in DBA2 and BKW mice mirror the expression 
levels of AT1 receptors found in this study; sug-
gesting that the more anxious strains exhibit 
higher levels of AT1 receptor expression.  Such 
differences in the protein level of AT1 receptors 
would also be of interest as well as possible 
effects of post-translational modifications in 
these strains. 
 
The previous strain dependent effect, whereby 
losartan is only effective in the BKW strain, may 
represent an effect due to the higher levels of 
anxiety inherently displayed by this strain, per-
haps due to this increased AT1 expression. 
Whether higher AT1 expression in the BKW 
strain results in an anxious phenotype or 
whether increased anxiety is due to increased 
upregulation of AT1 receptors remains unre-
solved; however overexpression of AT1 receptors 
in mice lacking AT2 receptors is linked with anxi-
ety-like behaviour [22].  In contrast, the pheno-
type of AT1 -/- mice may also be of interest in 
determining the role of these receptors in anxi-
ety. 
The use of more than one strain, when testing 
the mechanism and the role of AT1 antagonists, 
is not typical of this literature, possibly explain-
ing why the correlation between AT1 expression 
and an anxious phenotype may not have been 
identified previously. 
 
It is interesting to note that in the previous 
study by Gard et al, [5] the C57 and DBA2 
strains showed similar contractile responses to 
Ang II, while the BKW strain showed a signifi-
cant reduction. ATRAP is associated with re-
duced Ang II signalling and this study has identi-
fied that both DBA2 and BKW mice posses a 
non-synonymous polymorphism (rs13467517) 
in this gene.  ATRAP modifies Ang II receptor 
signalling in vitro and in DBA2 and BKW mice 
the SNP results in a non-synonymous Valine to 
Alanine amino acid change at position 157 of 
the hydrophilic domain of the protein. The pre-
cise effect of this polymorphism is unknown, 
and is only observational but it is tempting to 
speculate that the higher expression of AT1 re-
ceptors in DBA2 and BKW, in contrast to C57 
mice, is linked to this polymorphism.  
 
At present the discrete localisation of ATRAP is 
unknown, although low levels have been identi-
fied in the brain [14]. Perhaps increased AT1 
receptor expression also results in increased 
ATRAP expression. Functional differences in 
ATRAP also provide a possible explanation of 
the strain differences observed in contractile 
effects of Ang II in isolated tissue.  Despite 
showing no variation in receptor structure, con-
tractile effects were reduced in BKW strains. 
Owing to the presence of the ATRAP-SNP in 
DBA2 strains, it would be expected that the re-
duced contractile effect would also be observed 
in this strain. However, DBA2 and C57 mice 
showed comparable contractile effects, perhaps 
due to signalling by another mechanism result-
ing in a compensational loss in signalling.  
 
In agreement with previous studies AT1 recep-
tors appear to be implemented in anxiety like 
behaviour. The previously identified strain differ-
ences and the “order” of anxiety seen within 
and between strains may be attributed to varia-
tion in AT1 expression levels, where more anx-
ious animals show higher AT1 expression. 
Whether the changes in AT1 expression are me-
diated by the functional mutation in ATRAP, are 
due to posttranslational modifications or vari-
ability in protein levels or linked to SNPs in the 
promoter region was not specifically investi-
gated in this study. 
 
Importantly, current treatments focus on sero-
tonin, dopamine and noradrenaline in the brain 
and their efficacy and response rate has not 
improved despite the development of newer 
drugs [23]. Data show that specific antagonism 
of AT1 receptors reduces anxiety and therefore 
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suggests that levels of AT1 expression have an 
important role. Whether AT1 expression is the 
critical mediator of anxiety and whether higher 
AT1 receptor expression is indicative of an anx-
ious phenotype warrants further research. 
 
Please address correspondence to: Dr. BJ Gold-
ing, Department of Neuroscience, University of Ge-
neva, Switzerland. E-mail: bruno.golding@unige.ch 
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